Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more
Verona Pharma plc (I9SA) - Net Assets
Latest net assets as of June 2025: €278.27 Million EUR
Based on the latest financial reports, Verona Pharma plc (I9SA) has net assets worth €278.27 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€572.87 Million) and total liabilities (€294.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €278.27 Million |
| % of Total Assets | 48.58% |
| Annual Growth Rate | 21.69% |
| 5-Year Change | 10.66% |
| 10-Year Change | N/A |
| Growth Volatility | 115.98 |
Verona Pharma plc - Net Assets Trend (2016–2024)
This chart illustrates how Verona Pharma plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Verona Pharma plc (2016–2024)
The table below shows the annual net assets of Verona Pharma plc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €204.56 Million | -17.94% |
| 2023-12-31 | €249.28 Million | +8.16% |
| 2022-12-31 | €230.47 Million | +55.72% |
| 2021-12-31 | €148.00 Million | -19.93% |
| 2020-12-31 | €184.85 Million | +316.31% |
| 2019-12-31 | €44.40 Million | -44.40% |
| 2018-12-31 | €79.86 Million | -26.02% |
| 2017-12-31 | €107.95 Million | +153.84% |
| 2016-12-31 | €42.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Verona Pharma plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53367300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €766.96 Million | 374.93% |
| Total Equity | €204.56 Million | 100.00% |
Verona Pharma plc Competitors by Market Cap
The table below lists competitors of Verona Pharma plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WESCO International Inc
NYSE:WCC
|
$12.48 Billion |
|
Roku Inc
NASDAQ:ROKU
|
$12.48 Billion |
|
A.P. Møller - Mærsk A/S
PINK:AMKBF
|
$12.49 Billion |
|
Alibaba Health Information Technology Limited
PINK:ALBBY
|
$12.50 Billion |
|
Smith & Nephew plc
PINK:SNNUF
|
$12.44 Billion |
|
TCEYF
PINK:TCEYF
|
$12.44 Billion |
|
Allegion PLC
NYSE:ALLE
|
$12.39 Billion |
|
Inpex Corporation
PINK:IPXHF
|
$12.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Verona Pharma plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 249,283,000 to 204,559,000, a change of -44,724,000 (-17.9%).
- Net loss of 173,418,000 reduced equity.
- New share issuances of 97,496,000 increased equity.
- Other factors increased equity by 31,198,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-173.42 Million | -84.78% |
| Share Issuances | €97.50 Million | +47.66% |
| Other Changes | €31.20 Million | +15.25% |
| Total Change | €- | -17.94% |
Book Value vs Market Value Analysis
This analysis compares Verona Pharma plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 298.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 87.75x to 298.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €1.03 | €90.20 | x |
| 2018-12-31 | €0.76 | €90.20 | x |
| 2019-12-31 | €0.42 | €90.20 | x |
| 2020-12-31 | €0.40 | €90.20 | x |
| 2021-12-31 | €0.31 | €90.20 | x |
| 2022-12-31 | €0.38 | €90.20 | x |
| 2023-12-31 | €0.39 | €90.20 | x |
| 2024-12-31 | €0.30 | €90.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Verona Pharma plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -84.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -410.18%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 2.32x
- Recent ROE (-84.78%) is below the historical average (-41.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -14.56% | 0.00% | 0.00x | 1.34x | €-10.44 Million |
| 2017 | -25.66% | 0.00% | 0.00x | 1.12x | €-38.49 Million |
| 2018 | -31.62% | 0.00% | 0.00x | 1.18x | €-33.24 Million |
| 2019 | -94.32% | 0.00% | 0.00x | 1.33x | €-46.32 Million |
| 2020 | -35.24% | 0.00% | 0.00x | 1.10x | €-83.63 Million |
| 2021 | -37.55% | -138.92% | 0.21x | 1.26x | €-70.37 Million |
| 2022 | -29.81% | -15000.22% | 0.00x | 1.13x | €-91.75 Million |
| 2023 | -21.81% | 0.00% | 0.00x | 1.24x | €-79.30 Million |
| 2024 | -84.78% | -410.18% | 0.09x | 2.32x | €-193.87 Million |
Industry Comparison
This section compares Verona Pharma plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Verona Pharma plc (I9SA) | €278.27 Million | -14.56% | 1.06x | $12.46 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |